CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $264.97M, lower than 95% of all stocks globally
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
264.97MUSDvs all stocks (USD)
Revenue (TTM)
45.70MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.49xvs all stocks
52-Week Change
80.34%vs all stocks
Market Capitalization
264.97MUSDvs all stocks (USD)
Enterprise Value
111.40MUSDvs all stocks (USD)
Forward P/E
-2.57xvs Biotechnology peers
Price to Sales (TTM)
5.80xvs Biotechnology peers
Enterprise to Revenue
2.44xvs Biotechnology peers
Enterprise to EBITDA
-0.8860xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-301.73%vs Biotechnology peers
Return on Assets (TTM)
-36.08%vs Biotechnology peers
Revenue (TTM)
45.70MUSDvs all stocks (USD)
Revenue per Share (TTM)
3.92USDUpdated Sep 28, 2026Quarterly Revenue Growth
-84.60%vs Biotechnology peers
Gross Profit (TTM)
-99.04MUSDvs all stocks (USD)
EBITDA (TTM)
-125.80MUSDvs all stocks (USD)
Net Income (TTM)
-180.64MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-84.57%vs Biotechnology peers
Operating Cash Flow (TTM)
-145.17MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-100.76MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
102.48MUSDFY2025 · Dec 31, 2025Operating Income
-104.95MUSDvs all stocks (USD)
Pre-tax Income
-191.18MUSDFY2025 · Dec 31, 2025Income Tax Expense
-93.00KUSDFY2025 · Dec 31, 2025Net Income
-191.09MUSDFY2025 · Dec 31, 2025EBIT
-149.12MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-88.38MUSDFY2025 · Dec 31, 2025Research & Development
166.42MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
41.02MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
9.25MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
42.06MUSDFY2025 · Dec 31, 2025EPS (Basic)
-22.49USDFY2025 · Dec 31, 2025EPS (Diluted)
-22.49USDFY2025 · Dec 31, 2025Basic Shares Outstanding
8.50MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
8.50MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-191.09MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-198.39MUSDFY2025 · Dec 31, 2025Free Cash Flow
-200.09MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
58.99MUSDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-191.09MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
7.32MUSDFY2025 · Dec 31, 2025Stock-based Compensation
14.01MUSDFY2025 · Dec 31, 2025Other Non-cash Items
44.66MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
4.64MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-2.47MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-75.47MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.70MUSDFY2025 · Dec 31, 2025Purchase of Investments
-264.95MUSDFY2025 · Dec 31, 2025Sale of Investments
311.66MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
45.01MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-332.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-332.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
16.58MSharesUpdated Sep 28, 2026Float Shares
10.76MSharesUpdated Sep 28, 2026Shares Short
2.08MSharesUpdated Sep 28, 2026Short Ratio
7.43daysvs all stocks
Short % of Shares Outstanding
12.56%vs all stocks
% Held by Insiders
2.26%vs all stocks
% Held by Institutions
98.79%vs all stocks
Total Cash (MRQ)
164.35MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
9.91USDUpdated Sep 28, 2026Total Debt (MRQ)
10.78MUSDvs all stocks (USD)
Current Ratio (MRQ)
3.32xvs Biotechnology peers
Book Value per Share (MRQ)
-6.23USDUpdated Sep 28, 2026Total Assets
173.83MUSDvs all stocks (USD)
Total Current Assets
150.93MUSDFY2025 · Dec 31, 2025Total Liabilities
306.28MUSDFY2025 · Dec 31, 2025Total Non-current Assets
22.90MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
231.15MUSDFY2025 · Dec 31, 2025Total Current Liabilities
75.13MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
58.13MUSDFY2025 · Dec 31, 2025Other Short-term Investments
83.30MUSDFY2025 · Dec 31, 2025Accounts Receivable
3.98MUSDFY2025 · Dec 31, 2025Accounts Payable
7.57MUSDFY2025 · Dec 31, 2025Short-term Debt
7.78MUSDFY2025 · Dec 31, 2025Deferred Revenue
10.56MUSDFY2025 · Dec 31, 2025Other Current Liabilities
2.91MUSDFY2025 · Dec 31, 2025Long-term Debt
7.89MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.69MUSDFY2025 · Dec 31, 2025Common Stock (Book)
9.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-977.96MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-132.45MUSDvs all stocks (USD)
52-Week Low
7.15USDUpdated Sep 28, 202652-Week High
43.85USDUpdated Sep 28, 202652-Week Change
80.34%vs all stocks
Beta
1.49xvs all stocks
50-Day MA
20.92USDUpdated Sep 28, 2026200-Day MA
22.81USDUpdated Sep 28, 2026Avg 10-Day Volume
422.45KSharesUpdated Sep 28, 2026Avg 30-Day Volume
299.73KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-17.37USDUpdated Sep 28, 2026Other Income / Expense
-53.41MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $264.97M, lower than 95% of all stocks globallySignificant
Market cap (USD): 264,967,112Global P5: 275,556,405.438
Companies that share the same coordination system — how they create, deliver, or capture value.
TriSalus Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Greenwich LifeSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Oryzon Genomics S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Ginwa Enterprise Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Lineage Cell Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hunan Nucien Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tanvex Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Lexeo Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Northwest Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cresco Labs Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Sanxiang Advanced Materials Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Cabaletta Bio Inc.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
CommScope Holding Company, Inc.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown